Vantage Point

The latest thinking from our experts around the globe

banner_team at board
Latest Blog Post

How Horizontal Integration Can Drive Health System Innovation
Jim Featherstone explains how biopharmaceutical innovation is being stymied by traditional linear development.

What We Think About

Evidence & Value

Healthcare costs are climbing, regulators around the globe are requiring more information, and both providers and payers have higher expectations for a medical treatment’s proof of value before prescribing or paying for those treatments.
Key Topics
  • Consulting
  • Market Access and Commercialization
  • Patient-Centric Solutions
  • Real-World and Late Phase

Systems-Thinking

The healthcare industry is in a radical state of transformation, and biopharma players need to adapt to a systems-oriented approach to protect revenues, grow market share, and obtain regulatory approval for new treatments.
Key Topics
  • Clinical Trial Planning and Design
  • Market Access and Commercialization
  • Patient-Centric Solutions
  • Real-World and Late Phase

Payers & Providers

Payers and providers are steadily beginning to only pay for and prescribe treatments that improve patient outcomes, and despite how good a new product might be, it is only as good as how it is used in a real-world setting.
Key Topics
  • Consulting
  • Market Access and Commercialization
  • Patient-Centric Solutions
  • Real-World and Late Phase

Oncology

Advances in genomics and information technology are ushering in a new era for oncology drug development, but biopharmaceutical companies must move the conversation from cost to value.
Key Topics
  • Bioanalytical Laboratories
  • Clinical Trial Planning and Design
  • Data-Driven Trial Execution
  • Market Access and Commercialization
  • Real-World and Late Phase

Diabetes

As the prevalence of diabetes continues to increase globally, and the market for new therapies grows increasingly crowded, it's more important than ever to match the right drug to the right patient.
Key Topics
  • Clinical Trial Planning and Design
  • Model-based Drug Development
  • Real-World and Late Phase

Rare Diseases

Although regulatory incentives and the designation of “orphan” products have stimulated commercial research for rare diseases, their low prevalence, high complexity and predominance in children create significant barriers. Providers and patients are clamoring for treatment access and improved outcomes, but increasingly payers are making hard choices about reimbursing these therapies. 
Key Topics
  • Consulting
  • Market Access and Commercialization
  • Patient and Investigator Recruitment
  • Real-World and Late Phase

Biosimilars

Biosimilar development and commercialization is a uniquely difficult endeavor requiring precise, stepwise planning to ensure timely regulatory approval and optimal market access. 

Key Topics
  • Biosimilars
  • Consulting
  • Market Access and Commercialization
  • Regulatory Affairs

Quintiles Blog

Fresh ideas and insights from our experts around the globe.

Blog

Peer-Reviewed Publications
A data-driven approach to risk-based source data verification.
Therapeutic Innovation & Regulatory Science. 2014;48(2):173-180.
Read more
Recent Developments in the Prevention and Treatment of Missing Data
Therapeutic Innovation & Regulatory Science. 2014;48:68.
Read more
Randomized discontinuation trials with binary outcomes.
Journal of Statistical Theory and Practice. 2014.
Read more